CDKN2AIP Antibodies

Santa Cruz Biotechnology features a diverse variety of CDKN2AIP Antibodies for research in cell cycle regulation and tumor suppression. CDKN2AIP Antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CDKN2AIP, or CDKN2A interacting protein, plays a crucial role in regulating the cell cycle by interacting with key proteins involved in tumor suppression. CDKN2AIP's importance is demonstrated by its association with various cancers, making it a significant target for understanding tumorigenesis and developing therapeutic strategies. The study of CDKN2AIP can provide insights into the mechanisms of cell cycle control and the potential for targeted cancer therapies. Researchers can explore multiple aspects of CDKN2AIP function using specific antibody conjugates, including horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC). Understanding CDKN2AIP's role in cellular processes opens new avenues for cancer research and therapeutic development. Santa Cruz Biotechnology monoclonal antibodies for CDKN2AIP support researchers worldwide in advancing cancer biology and cell cycle regulation studies.